Strides Pharma Ltd has announced Consolidated financial results for the quarter ending December 31, 2022.
Financial Results (Q3 FY2023) – Quarter-over-Quarter Comparison:
Total income of Strides Pharma Ltd for Q3 FY2023 was Rs. 891.046 crores, a decrease from Rs. 920.556 crores in Q2 FY2023.
Net profit/loss for Q3 FY2023 was Rs. -80.026 crores, a decrease from a net profit of Rs. 22.825 crores in Q2 FY2023.
Earnings per share for Q3 FY2023 was Rs. -8.86, a decrease from Rs. 2.54 in Q2 FY2023.
Financials | Q3 FY2023 | Q2 FY2023 | % Change |
Total Income | ₹891.046 Cr | ₹920.556 Cr | 🠋 -3.21% |
Net Profit | ₹-80.026 Cr | ₹22.825 Cr | 🠋 -450.61% |
EPS | ₹-8.86 | ₹2.54 | 🠋 -448.82% |
Financial Results (Q3 FY2023) – Year-over-Year Comparison:
Total income of Strides Pharma Ltd for Q3 FY2023 was Rs. 891.046 crores, an increase from Rs. 804.582 crores in Q3 FY2022.
Net profit/loss for Q3 FY2023 was Rs. -80.026 crores, an improvement from a net loss of Rs. -121.671 crores in Q3 FY2022.
Earnings per share for Q3 FY2023 was Rs. -8.86, an improvement from Rs. -13.55 in Q3 FY2022.
Financials | Q3 FY2023 | Q3 FY2022 | % Change |
Total Income | ₹891.046 Cr | ₹804.582 Cr | 🠉 10.75% |
Net Profit | ₹-80.026 Cr | ₹-121.671 Cr | ⬇ 34.23% |
EPS | ₹-8.86 | ₹-13.55 | ⬇ 34.61% |
Financial Results (9 Months Ended FY2023) – Year-over-Year Comparison:
Total income of Strides Pharma Ltd for the 9 months ended December 31, 2022 was Rs. 2765.224 crores, an increase from Rs. 2250.163 crores in the same period of FY2022.
Net profit/loss for the 9 months ended December 31, 2022 was Rs. -193.093 crores, an improvement from a net loss of Rs. -489.430 crores in the same period of FY2022.
Earnings per share for the 9 months ended December 31, 2022 was Rs. -21.45, an improvement from Rs. -54.54 in the same period of FY2022.
Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
Total Income | ₹2765.224 Cr | ₹2250.163 Cr | 🠉 22.89% |
Net Profit | ₹-193.093 Cr | ₹-489.430 Cr | ⬇ 60.55% |
EPS | ₹-21.45 | ₹-54.54 | ⬇ 60.67% |
For More Latest News Click Here